CA
NZ
UK
AU
IND
US
The company operates with reported debt of $8.91 million against $9.61 million in cash and equivalents. These figures indicate a relatively stableLiquidityposition. However, Rockwell faces significant challenges as it continues to report declining revenues alongside negative net margins, drawing attention from investors who closely …
The Trump administration's ambitious proposal to unbundle the widely administered measles, mumps, and rubella (MMR) vaccine into three separate doses is encountering substantial pushback from both regulatory bodies and pharmaceutical manufacturers. The potential shift has introduced uncertainty for vaccine developers and public health officials …
Tiny Health has made headlines by securing the 208th spot on the 2026 Inc. 5000 list, marking it as one of America's fastest-growing private companies. This recognition is a testament to its impressive revenue growth of 1,624% from 2022 to 2025, notably outpacing many …
Charlotte's Web Holdings, Inc. (OTC: CWBHF), a leader in botanical wellness products, reported significant improvements for the second quarter of 2026. The company achieved a gross margin of 47.5% and successfully reduced operating cash use to $0.9 million. This marks a notable advancement from …
Cellectar Biosciences, Inc. (NASDAQ: CLRB) trades with aMarket Capitalisationof $21 million and a float of 8,252,108 shares, while holding $33.99 million in cash and equivalents. At the close of the June 30, 2026 quarter the cash balance was reported at $34.0 million, reflecting a …
Cytokinetics, Incorporated (NASDAQ: CYTK) operates in the pharmaceuticals sector with a market valuation of $10.1 billion. The company recently reported revenues of $88.04 million and maintains approximately $255.27 million in cash and equivalents against aDebtload of $275.56 million. With a negative netMarginof -1321.1%, it …
Grace Therapeutics, Inc. (NASDAQ: GRCE) operates as a late-stage biopharmaceutical company with a market capitalization of $34 million. It is specifically focused on developing GTx-104, an injectable formulation aimed at progressing through the regulatory gauntlet for treating aneurysmal subarachnoid hemorrhage (aSAH). Recently, the company …
Lucid Diagnostics Inc. (NASDAQ: LUCD) operates within the healthcare sector as a commercial-stage medical diagnostics company focused on cancer prevention, boasting a marketCapitalizationof approximately $195 million. Despite facing net losses, Lucid continues to build momentum, reporting $1.5 million in revenue for the second quarter …
Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) is a clinical-stage biopharmaceutical company dedicated to developing therapies for cancer, demonstrated by its marketCapitalizationof approximately $1 billion. The company reported zeroRevenuein the past year, reflecting its focus on research and development, while holding significant cash and equivalents of …
PTC Therapeutics, Inc. (NASDAQ: PTCT) commands a market capitalization of roughly $6.2 billion and reports a price‑to‑sales multiple of 6.7. The firm generated $1.01 billion in trailing‑twelve‑month revenue, a 42.8% decline year‑over‑year, and posted a netMarginof -3.8%. With 991 employees, $1.05 billion of cash …
Please wait processing your request...